EZH2 and acute myeloid leukemia: Furthermore, in the French national ELAM02 study which involved 222 pediatric AML patients, the results suggested that mutations and deletions in the core components of PRC2 (EED, SUZ12 and EZH2) resulted in a subgroup of pediatric AML patients who presented a particularly aggressive disease (Papaemmanuil et al., 2016).